clonoSEQ MyChart Fact Sheet

What is clonoSEQ (clo-no-seek) testing?

clonoSEQ is a measurable residual disease (MRD) test, that can detect the number of cancer cells that may remain in your body during and after therapy.

Your doctor's ability to detect these traces of disease may be important for making timely and informed decisions about your treatment plan.

clonoSEQ is a two-part test; we need to identify at least one dominant DNA sequence, associated with your cancer, with a Clonality (ID) test before Tracking (MRD) testing can be performed.

clonoSEQ is FDA-cleared for multiple myeloma (MM), CLL, and ALL, and it is CLIA-validated for DLBCL, MCL, and other lymphoid cancers.

Measuring MRD with clonoSEQ can help you and your doctor:



Learn More

clonoSEQ MRD Testing:
Visit clonoSEQ.com or call Adaptive clonoSEQ Customer Service Team at 1-888-552-8988

Patient Support & Financial Assistance:
Visit Adaptive-Assist.com or call the Adaptive Assist Help Line at 1-855-236-9230

Reading your clonoSEQ results:

clonoSEQ Clonality (ID) report

Sample report for a patient enabled for future clonoSEQ Tracking (MRD) tests.

CLONALITY RESULT

4 Dominant Sequences Identified
Patient Enabled for MRD Tracking

Sample report for a patient not enabled for future clonoSEQ Tracking (MRD) tests.

CLONALITY RESULT

No Dominant Sequence Identified (Polyclonality)
Clone tracking (e.g. MRD determination) is not enabled by this sample

clonoSEQ Tracking (MRD) report

Sample MRD-positive clonoSEQ report showing residual disease was present in the sample tested.

SAMPLE-LEVEL MRD RESULT

\+ **Residual Sequences Detected**
ESTIMATED MRD VALUE:
159 residual clonal cells per million nucleated cells (Range: 105 - 235)
Total nucleated cells evaluated from this sample: 3,444,153

Sample MRD-negative clonoSEQ report showing no evidence of residual disease in the sample tested.

SAMPLE-LEVEL MRD RESULT

No Residual Sequences Detected
ESTIMATED MRD VALUE:
0 residual clonal cells (Range: 0 - <1)
Total nucleated cells evaluated from this sample: 3,500,194

The MRD range presented above represents the 95% confidence interval for the measured number of residual clonal sequences per million nucleated cells. Details for each identified dominant sequence from this sample are provided on subsequent pages of this report.

Questions to consider asking your doctor:

What other tests are important to consider in context with my clonoSEQ results?

How might clonoSEQ MRD results help inform and shape my treatment plan?

Is MRD negativity a reasonable goal for me?

At what timepoints during or after treatment should I receive clonoSEQ MRD testing?

Why is ongoing clonoSEQ MRD testing important?

When might blood-based clonoSEQ MRD testing be right for me?

Please note: If you are enrolled in a clinical trial, access to clonoSEQ results may be limited, and results may not be available in MyChart.

You should consult your doctor to discuss this result in context with your disease state, other tests, and/or previous clonoSEQ results.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

MyChart® is a trademark of Epic Systems Corporation.

PM-US-cSEQ-1245-1